In addition, due to limited data on compound-specific carcinogenic potency, the carcinogenic potencies of AFB2, AFG1, and AFG2 were assumed to be equivalent to that of AFB1, which may have led to a slight overestimation of the total risk from AF exposure. The gene discussed is AFG1L; the disease is atrial fibrillation.